Johnson & Johnson (JNJ)
These 3 Dividend Stocks Have Survived Every Recession Since 1970. Retirees Trust Them for a Reason.
Retirees rarely want excitement from an income holding. They want a check that arrives, gets bigger, and does not care what the economy is doing.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
China approves J&J's oral psoriasis pill, says drugmaker
China's drug regulator has approved Johnson & Johnson's oral pill for psoriasis, the company said on Thursday, intensifying competition in the world's second-largest pharmaceutical market with rivals including Bristol Myers Squibb and AbbVie.
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05% move from the preceding trading day.
5 Blue-Chip Dividend Stocks to Buy Before August Ends
August is winding down, and income-focused investors have a narrow window to line up ex-dividend dates before the calendar turns.
J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA
JNJ's Imaavy wins FDA approval for wAIHA, becoming the first treatment specifically indicated for the rare autoimmune disease.
Johnson & Johnson Is Near a Record High. Is There Still Room to Run?
At $270.24, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.
J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead
JNJ's pipeline remains a key growth driver, with new launches, late-stage data and approvals supporting momentum through the rest of 2026 and beyond.
Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push
Johnson & Johnson (JNJ) maintains a 'Buy' rating, driven by robust Q2 2026 sales growth and pipeline advancements. JNJ's top-performing drugs, DARZALEX and TREMFYA, fueled a 6.6% revenue increase to $25.3 billion, prompting raised full-year 2026 guidance. CAPLYTA's label expansion for schizophrenia relapse prevention and IMAAVY's potential first-mover status in wAIHA represent major growth catalysts.
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.
Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.
Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.
